Form 4: Jazz Pharma Officer Sells Shares, Exercises Options
Insider Transaction Report
Patricia Carr, SVP and Chief Accounting Officer of Jazz Pharmaceuticals, reported exercising stock options and selling ordinary shares on December 5, 2025.
Summary
- Patricia Carr, SVP, Chief Accounting Officer of Jazz Pharmaceuticals plc, reported transactions on December 5, 2025.
- Exercised 4,500 non-qualified stock options at an exercise price of $140.67 per share.
- Sold 4,500 ordinary shares at a weighted average price of $171.2012.
- Sold an additional 160 ordinary shares at $171.11.
- Acquired 160 ordinary shares under a Section 423 Employee Stock Purchase Plan on November 28, 2025.
- Beneficial ownership of ordinary shares decreased from 11,512 to 7,012 following these reported transactions.
Sentiment
Score: 5
Explanation: The filing reports routine insider transactions involving stock option exercise and subsequent share sales, which are common for executive compensation and personal financial planning. It does not reflect on the company's operational performance or future prospects directly.
Positives
- An executive exercised stock options, indicating a realization of value from previously granted equity.
- The exercise price of $140.67 was significantly lower than the sale prices of $171.11 and $171.2012, demonstrating a profitable transaction for the officer.
Negatives
- The sale of 4,660 ordinary shares by a senior officer could be interpreted as a reduction in direct equity exposure, although such sales are often for liquidity or tax planning purposes.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: The transactions represent a routine disclosure of an executive's personal stock activity, with minimal direct impact on the company's operational or strategic direction.
Key Dates
| Date | Description |
|---|---|
| March 1, 2018 | Grant date of the non-qualified stock options. |
| March 1, 2022 | Date when the non-qualified stock options fully vested. |
| November 28, 2025 | Acquisition of 160 ordinary shares under a Section 423 Employee Stock Purchase Plan. |
| December 5, 2025 | Date of option exercise and ordinary share sales. |
| December 9, 2025 | Signature date of the reporting person's attorney-in-fact for the filing. |
Recommendation
holdThis Form 4 filing details routine insider transactions by a company officer, involving the exercise of stock options and subsequent sale of shares. Such transactions are common for executive compensation and personal financial management and do not typically indicate a change in the company's fundamental outlook or warrant a shift in investment recommendation based solely on this disclosure.
Keywords
Jazz Pharmaceuticals, JAZZ, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.